0001354457-17-000090.txt : 20170428
0001354457-17-000090.hdr.sgml : 20170428
20170428092601
ACCESSION NUMBER: 0001354457-17-000090
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20170428
DATE AS OF CHANGE: 20170428
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: OSIRIS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001360886
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 710881115
STATE OF INCORPORATION: MD
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32966
BUSINESS ADDRESS:
STREET 1: 7015 ALBERT EINSTEIN DRIVE
CITY: COLUMBIA
STATE: MD
ZIP: 21046
BUSINESS PHONE: 443-545-1819
MAIL ADDRESS:
STREET 1: 7015 ALBERT EINSTEIN DRIVE
CITY: COLUMBIA
STATE: MD
ZIP: 21046
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NASDAQ Stock Market LLC
CENTRAL INDEX KEY: 0001354457
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
25-NSE
1
primary_doc.xml
X0203
0001354457
NASDAQ Stock Market LLC
0001360886
OSIRIS THERAPEUTICS, INC.
001-32966
7015 Albert Einstein Drive
Columbia
MD
MARYLAND
21046
443 545-1819
Common Stock
17 CFR 240.12d2-2(b)
Amy Horton
Hearings Advisor
2017-04-28
EX-99.25
2
osirdelistreason.txt
Delisting Determination,The Nasdaq Stock Market, LLC,
April 28, 2017, Osiris Therapeudics, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the common stock of Osiris Therapeudics, Inc.
(the Company), effective at the opening of the trading
session on May 8, 2017. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5250(c)(1).
The Company was notified of the Staffs determination on
September 14, 2016. The Company appealed the determination
to a Hearing Panel. Upon review of the information provided
by the Company, the Panel issued a decision dated
December 1, 2016, granting the Company continued listing
pursuant to an exception that included several milestones
that the Company was required to meet, towards the toal
of regaining compliance with Listing Rules 5250(c)(1) and
5620(a). However, the Company was
unable to meet the exception milestones as required.
On March 10, 2017, the Panel issued a final delisting
determination and notified the Company that trading in the Companys
securities would be suspended on March 14, 2017.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company
became final on April 24, 2017.